11,549 Shares in Vir Biotechnology, Inc. (NASDAQ:VIR) Purchased by Bank of Montreal Can

Bank of Montreal Can acquired a new position in shares of Vir Biotechnology, Inc. (NASDAQ:VIR) in the second quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 11,549 shares of the company’s stock, valued at approximately $292,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of VIR. Signaturefd LLC grew its position in Vir Biotechnology by 1,313.0% in the 1st quarter. Signaturefd LLC now owns 1,300 shares of the company’s stock valued at $30,000 after acquiring an additional 1,208 shares in the last quarter. Tucker Asset Management LLC acquired a new position in Vir Biotechnology in the 1st quarter valued at about $46,000. Captrust Financial Advisors grew its position in Vir Biotechnology by 1,270.7% in the 2nd quarter. Captrust Financial Advisors now owns 1,823 shares of the company’s stock valued at $46,000 after acquiring an additional 1,690 shares in the last quarter. Quantbot Technologies LP acquired a new position in shares of Vir Biotechnology during the first quarter worth about $64,000. Finally, Royal Bank of Canada grew its position in shares of Vir Biotechnology by 14.1% during the third quarter. Royal Bank of Canada now owns 4,125 shares of the company’s stock worth $79,000 after buying an additional 510 shares in the last quarter. 67.05% of the stock is owned by institutional investors and hedge funds.

Vir Biotechnology Stock Up 1.1 %

VIR stock opened at $9.80 on Tuesday. The business has a 50 day moving average price of $8.92 and a 200 day moving average price of $16.13. The stock has a market cap of $1.32 billion, a price-to-earnings ratio of -2.18 and a beta of 0.31. Vir Biotechnology, Inc. has a fifty-two week low of $7.72 and a fifty-two week high of $31.55.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on VIR shares. HC Wainwright lowered their price objective on Vir Biotechnology from $100.00 to $95.00 and set a “buy” rating for the company in a research report on Monday, August 7th. Needham & Company LLC lowered their price objective on Vir Biotechnology from $22.00 to $15.00 and set a “buy” rating for the company in a research report on Friday, November 3rd. Finally, Bank of America downgraded Vir Biotechnology from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $23.00 to $14.00 in a research report on Friday, September 8th. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $36.33.

About Vir Biotechnology

Vir Biotechnology, Inc, a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus.